title: Steroid-induced mandibular bone loss in relation to marginal periodontal changes.
abstract: Long-term high-dose glucocorticosteroid treatment may be suspected as causing profound marginal periodontal bone loss due to the immunosuppressive/antiinflammatory effects and due to the osteoporotic side-effects. This study comprised an analysis of the loss of the mandibular and forearm bone mineral content (BMC), measured in vivo by dual-photon scanner, in relation to the concomitant changes of the periodontal indices (visible plaque, gingival bleeding, loss of attachment) in 17 acute nephrotic dentate patients undergoing intensive steroid treatment for 12 months. The measurements were performed at start of treatment, when all patients were considered healthy as regards the skeleton, and at the 6-month and 12-month follow-up. The mean BMC loss at the standard sites of the mandible and the forearm bones was 5.6%/year at both sites. No significant changes could be demonstrated in the periodontal indices (P greater than 0.10), and no relation was found between the mandibular BMC loss and the periodontal condition (R = 0.06, P greater than 0.10). In conclusion, profound marginal periodontal bone loss does not seem to be a prominent side-effect of long-term glucocorticosteroid treatment, although the degree of induced osteopenia in the mandible corresponds to that in other cortical bones of the skeleton.
authors.affiliation: Department of Oral & Maxillofacial Surgery, Royal Dental College, Copenhagen, Denmark.
authors.forename: N
authors.initials: N
authors.lastname: von Wowern
authors.forename: B
authors.initials: B
authors.lastname: Klausen
authors.forename: K
authors.initials: K
authors.lastname: Olgaard
mesh_terms: D000328:Adult; D016301:Alveolar Bone Loss / Q000139:chemically induced*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects*; D015519:Bone Density / Q000187:drug effects; D001862:Bone Resorption / Q000139:chemically induced* / Q000378:metabolism; D003773:Dental Plaque / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D005542:Forearm; D005884:Gingival Hemorrhage / Q000473:pathology; D006801:Humans; D008297:Male; D008334:Mandible / Q000737:chemistry; D008336:Mandibular Diseases / Q000139:chemically induced* / Q000378:metabolism; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000188:drug therapy; D010510:Periodontal Diseases / Q000139:chemically induced*; D010514:Periodontal Pocket / Q000473:pathology; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects*; D011282:Pregnenediones / Q000008:administration & dosage / Q000009:adverse effects*; D013997:Time Factors
chemical_list: D000893:Anti-Inflammatory Agents; D011282:Pregnenediones; C021988:deflazacort; D011241:Prednisone